When an East Texas jury smacked a drug manufacturer with $23.4 million in damages Aug. 6 in the first fen-phen case to reach a verdict, the message the Canton trial sent to lawyers was clear: The price of settling America’s newest mass tort case just went up.

From Hawaii to New Jersey, thousands of fen-phen suits are pending against American Home Products Corp. So far, talks of a national settlement involving the diet drug � taken off the market in 1997 because of its link to heart problems � have failed. However, that may soon change.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]